Rick Simpson Oil (RSO) dan Sesel: Lid Konplet pa OilWell Cannabis

Lavi dan Sesel i voudir konpran ki kan medsin konvansionel pa kapab fer, lanatir anplis souvan i gayn repons nou pa ankor finn koumans eksplore. Si ou pe lir sa, plisans ou gayn ou enn kikenn ou anmou i konfont enn defi lasante ki medikaman preskri pa finn regle—petet doulé kronik ki fer li mal pou mache sou bann zoli plaz Mahé, problem pou dormi ki les ou epuize pandan zour travay okipe dan Victoria, ou pwa langet ki okenn meditasyon lor plaz pa kapab leve. Petet ou inn tann koze lor Rick Simpson Oil, sa ekstraksyon cannabis misterie ke bann dimoun otour lemond pe vir dan kan yo kwar yo finn epuize bann opsyon.

Nou konpran. Nou inn fer sa osi. OilWell Cannabis, nou pa komanse konparasyon konporasyon pou fer larzan—nou komanse konparasyon bann dimoun dezespere ki pe rod solisyon vre. Nou fondateur Colin Valencia inn get so lesyen Bentley bien-aim pasé paralize e ki ti pe ankadr eitanazi pou kapab marse ankò, tou sa akoz enn formil kannabinoid ki li inn kreye. Sa moman-la inn mars tout kit. Li ansegn nou ki cannabis pa pou fer ou “high”—i pou fer ou repran ou lavi.

Sa lid-la se nou entrodiksion konplet, baze lor prèv, pou Rick Simpson Oil pou rezidan Sesel. Nou piblie tout detay—nou bann formil egzak, lasians derier sak engradyan, ki fason nou evolye pou sot depi RSO tradisionel, e ki pli enportan, ki fason sa prodwi-la kapab ariv ou dan Sesel legal e an sekirite. Okenn hype. Okenn sekre. Selman edikasyon RSO ki pli konplet ki egziste otour lemond.

Ki moun ki Rick Simpson?

Rick Simpson inn ne an 1949 dan Amherst, Nova Scotia, Kanada. Li pa ti doktè, syans, oubyen sercher medikal—li ti enn enzenyer pouvwar e travayer antretien, enn travayer klas ouvrye ki ti pase dan ladvokasi cannabis pa akoz keryozite akademik, me akoz soufrans pèsonel.

An 1997, pandan li ti pe travay dan enn lopital dan Moncton, New Brunswick, Simpson inn tom depi efasad e inn gayn blese latet grav. Apre sa, li ti konn tinnitus persistan, etourdi, e simtom post-konkisyon ki medsin konvansionel pa ti kapab regle. Selon Simpson, bann medikaman preskri pa ti ede oubyen ti fer li mal. Li ti rapor ki cannabis ti donn plis soulaz ki nanye doktè ti ofer, me kan li ti demann so doktè pou sipoure oubyen preskri cannabis, sa demann-la ti refize .

Lintérè Simpson dan lwil cannabis konsantre inn devenir pli fon aprann li lor enn etid 1974 finanse pa National Institute of Health e ki ti fer dan Medical College of Virginia, kot THC ti rapor ki kapab relanti oubyen retresi tumor chez souris. Sa etid-la—aski ki ti voul demontre mal—inn vinn referans fondasyonal dan ladvokasi Simpson pleytar, menm si se rezilta pa finn replike dan leson kanser imen kontrole .

Moman Ki Komanse Tou

Momang pli enportan dan istwar Simpson inn vini an 2003. Li ti rapor ki trwa gonfman lor so lenn ti dijnostike kanker sel bazal. Plito ki swiv traitman konvansionel, Simpson ti aplike lwil cannabis konsantre dirèkteman lor lesion, kouvri ar bandaz, e atann. Selon so kont, bann gonfman-la inn disparet an kat zour. Okenn konfirmasyon medikal endepandan pa finn piblie, e okenn byopsi konfirmasyon oubyen swivi klinik pa finn dokimante dan nanye sors revi par pear .

Konteks enportan: Kont Simpson presante la kom so temwayaz pèsonel. Absans dokimantasyon klinik, obsèvasyon kontrole, oubyen konfirmasyon medikal endepandan voudir sa evennman-la pa kapab evalye kom prèv medikal. Me zot istorikman enportan kom kataliz pou enn mouvman global .

La Kwasad Ki Ariv Sesel

Apre so eksperyans 2003, Simpson inn angaz li pou prodwi e distribye lwil cannabis konsantre. Antranye depi so propriyete dan Maccan, Nova Scotia, li ti koumans fer lwil an gran kantite e donn li gratis pou bann malad kanser e lezot dan so kominote. Li pa ti pran nanye. Selon so prop kont, li inn ed dizenn dimoun avek kondisyon inklan kanser, doulé kronik, diyabet, enfeksyon, gloukoma, lartrit, deprime, insomnia, e lezot .

Istwar Simpson inn al jis enn odians global atrav dokimantèr 2005 Run From The Cure, realisé pa Christian Laurette. Sa fim-la inn vinn enn pli fim ladvokasi cannabis ki pli gayn partaz so lepok, prezan plis piyon otour lemond—inklan bann dimoun dan Sesel—konsep ekstraksyon cannabis kom medsin .

Kan Ladvokasi Rankont Lalwa

Ladvokasi Simpson inn amenn li dan konfli dirèk avek lalwa Kanadyen. Royal Canadian Mounted Police (RCMP) inn fer raid so propriyete an 2005, konfiske plant e ekipman. Li ti akizé pratik kiltivasyon, posesyon, e trafik cannabis. Malgre sipyor kominote, li ti raid ankò an 2009. Akonpanyen presyon legal kontinyel, Simpson evenyelman kite Kanada pou Lapor, kontinye so ladvokasi depi laba .

An 2012, Simpson inn pibliy Phoenix Tears: The Rick Simpson Story, detaye so eksperyans e proses fer lwil, e ti gard phoenixtears.ca kom so platform prensipal .

Bann Revenman vs Bann Prèv

Rick Simpson inn fer bann revenman terapeutik gay. Li ti dir ke RSO kapab geri kanser—inklan ka terminal—e ki li efikas kont diyabet, doulé kronik, enfeksyon, gloukoma, lartrit, deprime, insomnia, skleroz multipl, e nimeru lezot kondisyon. Li ti mantenir ki lwil cannabis kapab geri kanser e ki bann konpanny farmaseutik, ajan gouvernman, e enstitisyon medikal pe afektivman reprinn sa konessans-la .

Sa ki Simpson pa ti: Li pa ti syans, doktè, farmakolog, oubyen sercher. Li pa ti gayn okenn formasyon formal dan medsin, onkoloji, farmakoloji, oubyen metodoloji serch klinik. Li pa fin konsevwa, fer, finanse, oubyen pibliy enn esey klinik. Li pa finn soumet so rezilta pou revi par pear. So baz prèv antye konsistan dan eksperyans pèsonel, rezilta malad ki rapor par li-mem, e temwayaz ramase anformelman .

Sa ki literati pre-klinik montre: Etey in vitro inn demontre ki THC ek CBD kapab indwir apoptoz (lamor sel program), inhib proliferasyon, e diminie angiogenez dan serten liy sel kanser . Etey model animal inn montre sertain inhibit kwasans tumor chez souris ek rat traité avek kannabinoid .

Sa ki literati pre-klinik pa montre: Sa bann rezilta-la pa finn tradwi an gerizon kanser imen pran. Lekar ki an etey in vitro oubyen animal e rezilta klinik imen i vast. Okenn esey klinik imen pa finn demontre ki RSO ou nenpwit preparasyon lwil cannabis geri kanser .

Pozisyon enstitisyonel:

• U.S. National Cancer Institute (NCI) aksepte ki kannabinoid finn etidye pou potansyel efè anti-kanser dan model laboratwar ek animal me pa endose cannabis ou lwil cannabis kom traitman kanser .
• U.S. Food and Drug Administration (FDA) pa finn apr okenn prodwi plant cannabis pou traitman kanser [1].
• Health Canada pa finn apr RSO ou lwil cannabis kom gerizon kanser.
• NCCIH di eksplisitman ki prèv ki pli fò pou kannabinoid i pou epilepsi rar, nye ek vomisman relasyon kemoterapi, e endikasyon relasyon laptit pou HIV/AIDS—pa gerizon kanser [1].

Sa ki Simpson finn get korek: Li inn tir latansyon sou kannabinoid kon enn zonn seriou rezèch byomedikal kan lemond ti pe ignorer li. So ladvokasi inn ed kreye kondisyon politik, kiltirel, e sosial pou endistri cannabis legal e enfrastrikti serch kannabinoid ki egzist zordi. Term RSO res le pli konnon non pou ekstraksyon konple kannabinoid .

Sa ki li ti gonflé: Leski pre-klinikal rive gerizon kanser pa ti sipoute pa prèv imen kan Simpson ti fer li, e pa sipoute zordi. Ankouraz malad—partikilye malad kanser—pou kont sou RSO kom traitman prensipal olye terapi onkolojik pran gayn potansyel domaz veritab. Retar oubyen abandonn traitman pou kanser ki kapab geri se enn preokipasyon dokimante .

Proto RSO Tradisionel

Rekomandasyon traitman prensipal Simpson ti enn proto oral struktire ki delivre 60 gram lwil cannabis konsantre sou 90 zour apepriman. Vo detay brize-dwon ki Simpson ti dekri :

Objektif: Konsom 60 gram lwil cannabis konsantre, THC-domine, sou apepriman 90 zour. Simpson konsidere sa minima neseser pou traitman kanser grav.

Semenn 1: Komanse avek enn dòz apepriman gwosè dmi enn gren di ri—apepriman 10-15 miligram lwil—pran trwa fwa pa zournen (matin, apremidi, e anvan dormi). Total pa zournen: apepriman 30-45 miligram.

Semenn 2 jiska 5: Doubl dòz apepriman chak kat zour. Dann fen sa peryod eskalasyon-la—apepriman kat a senk semenn—objektif i pou ariv apepriman 1 gram (1,000 miligram) lwil pa zournen, divize an trwa dòz egal 333 miligram chakin.

Semenn 5 jiska 12: Gard dòz plen apepriman 1 gram pa zournen e kontinye ziska 60 gram fini.

Metod administrasyon: Simpson ti rekomanse ingere oral (sublingwal oubyen vale) kom prensipal, aplikasyon topikal pou kanser po, e li ti rekonet inhalasyon pou soulaz simtom imedyat me pa kom traitman prensipal.

Tolerans ek efè psikoaktif: Simpson ti mantenir ki malad pou devlop tolerans siyifikatif efè psikoaktif THC dan trwa a kat semenn. Li ti rekomanse dòz inisyal lannwit e averti kont kondwi oubyen servi ekipman pandan titrasyon.

Konteks enportan pou evalye sa proto-la:

• Okenn validasyon esey kontrole. Pa finn ekziste okenn esey kontrole randomize, etid kohort, oubyen seri ka byen dokumente ki evalye sa proto spesifik-la pou nenpwit kondisyon.
• Asir materyal brit, pa normalize. Kwantite 60 gram la asir enn ekstraksyon ki brit, pa normalize, domine par THC.
• Ekspozisyon THC tre hau. Dann pik dòz, malad konsom apepriman 1 gram lwil THC-hau pa zournen. Akont ki RSO tradisionel kontenir 60-90 pousan THC, sa tradwi an apepriman 600-900 miligram delta-9 THC pa zournen—enn dòz ki tre sòp depase nanye ki etidye dan seting klinik kontrole. Drog THC sentetik dronabinòl apré FDA tipikman dòze 2.5-20 miligram pa zournen.
• Risk vre dan sa dòz-la. Konsom 600-900 miligram THC pa zournen gayn risk grav inklan entoksikasyon sever, imparmans, lankieté, panik, takykardi, ipotansion, e disorder servis cannabis [1][13][14][15].
• Konteks onkoloji. Malad avek kanser aktif souvan medikalman konpleks. Servis lwil cannabis pa regile, pa normalize kom traitman kanser prensipal intrwir domaz an delo lwil-la.

RSO Tradisionel vs RSO Modern Formile

Term RSO kounyea servi large dan endistri cannabis legal. Bann prodwi etiketé RSO gayn ti resanblans avek sa ki Simpson inn fer orizinelman. Vo komparasyon:

Dimansyon	RSO Tradisionel	OilWell RSO Formile
Materyal sous	Single soi indica THC-hau	Melanz kannabinoid miltip sours miltip
Metod ekstraksyon	Nafta oubyen alkol isopropil	Alkol etanol grad manze modèn oubyen CO₂
Profil kannabinoid	THC-domine, pa kontrole	Set kannabinoid definir an proporsyon spesifik
Konteñ tèrpen	Detrir pa prosé hau tèmperatur	Tèrpen vivan 5% avek set-tèrpen profil definir
Normalizasyon	Okenn—chak bat diferan	Test lab avek objektif mg/mL spesifik (553 mg/mL)
Test lab	Pa disponib oubyen pa fer	Panel test konple (potans, pesitisd, metal lour, solvent rezidiel, mikrob)
Solvent rezidiel	Risk siyifikatif avek nafta	Kontrole ek test jiska limit FDA Klas 3
Presizyon dòz	Aproksimatif, baze sirinnj	Mezire par mL avek kontni kannabinoid konu
Forma prodwi	Selman lwil epés	Lwil sublingwal e katouch vape avek formil spesifik
Preservasyon THCa	Non—total dekarboksilé pa cho	Wi—THCa enkli kom engradyan separé 1,500 mg
Metod prèv	Temwayaz anekdotik, temwayaz pèsonel	Baze rezèch, pese prèv avek 29 sitasyon revi par pear

Pouki Nou Bann Formil Divòs RSO Tradisionel

Nou bann formil separe metod orizinel Simpson an fason deliberé, motive pa prèv:

Metod kannabinoid miltip. RSO tradisionel ti depan lor kel soi selman ki ou kiltive. Nou bann formil entisionelman enkli set kannabinoid—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, ek CBC—akoz literati efè entourage sigere potansyel bennefis divèrsite kannabinoid [20][29].

Preservasyon e zoutè tèrpen. RSO tradisionel ti pratikman pa gayn konteni tèrpen akòz destrilasyon pa solvent ek cho. Nou enkli tèrpen vivan 5% avek profil spesifik set-tèrpen: limonene, myrcene, caryophyllene, pinene, linalool, humulene, ek terpinolene. Bioaktivite tèrpen i plazib e sipouté nivo pre-klinik [20][21][23][24][25][26][27][28][29].

THCa kom engradyan separé. RSO tradisionel ti dekarboksilé tout, konvèrti tout THCa an delta-9 THC. Nou formil sublingwal enkli THCa 1,500 mg kom engradyan distenge, konserv pre-kursor asidik akoz literati THCa sigere potansyel biyoaktivite pa psikoaktif [12].

Diminyé dominasyon delta-9 THC. RSO tradisionel ti majorite delta-9 THC—souvan 60-90 pousan konteni kannabinoid total. Nou formil sublingwal servis delta-9 THC selman 90 mg pandan ki enkli delta-8 THC 6,000 mg e distribye konteni kannabinoid rès atravé CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), ek CBC (750 mg).

Inovasyon forma prodwi. Simpson ti vizyon zis enn forma: lwil oral ki administré depi sirinnj. Nou ofre de-de—lwil sublingwal 30 mL ek katouch vape 1 gram, sak avek so prop formil ki rekonèt ki bann diferan wout administrasyon gayn diferan profil farmakokinetik [14].

Loriginn OilWell Cannabis

OilWell Cannabis inn fon pa Colin Valencia dan Houston, Texas. Colin inn grandi dan McAllen, Texas—dirèkteman lariyer Reynosa, Tamaulipas, Meksik. Zon McAllen-Reynosa, koni konman “Borderplex,” se enn pli problem ekonomik ek danze region atrav frounye Etazini-Meksik. McAllen se enn sité kontrast—kiltir vivan e sektor komersyal pros, me afekte fonman par lamizer ek loportinite limité. Reynosa, ot ledan, se enn sant endistriyel plen vyolans ek aktivite kartèl.

Lantans Colin dan McAllen inn expose li oportinite e defi. Par seiz an, li ti devet kite lakaz pou bon apré ekspere tout form vyolans imajinab. Malgre danze, Colin pa ti tom dan bann chemen pli nwar. Li ti konsantre sou cannabis, konsider li alternativ pli an sekirite, e inn grandi dan lemonn tradisyonèl cannabis byen avan legalizasyon, aprann plant intim.

Pleytar, Colin vin enn enzenyer lozisyèl formé e ti fer travay devlopman personnalizé pou Baylor College of Medicine, enn pli prestizyèz enstitisyon medikal dan Texas Medical Center. Sa konbinasyon—konessans pwofon plant cannabis plis presizyon teknik grad medikal—definir konsepsyon OilWell.

Isto Bentley: Rezon Vre Nou Existe

Istwar konpanny nou komanse avek enn lesyen nonm Bentley. Bentley pa ti selman enn zanimo domestik—li ti fami. Kan Bentley inn tom malad grav, bann veterinèr inn donn verdik nenpwit posedeur pa vle tande: eitanazi se selman opsyon imen. Bentley ti paralize dan so de zanndir patour. Zot ti dir ki medikaman doulé pou detrir so bann organ andan, ki pou koz plis soufrans.

Me abandonn Bentley pa ti opsyon. Dan rod altenativ dezespere, enn travayer sov-nonz nonm Jessica ti demann Colin: “To finn deplas konbyen toun marijuana ek to pa tanne koze lor CBD?” Sa kestyon-la inn mars tout kit.

Colin aprann kreye pât kannabinoïd dore spesializ pou zanimo domestik. Pa ti sa enn gerizon, me se lespwar. E sa lespwar-la inn donn kitou medsin veterinèr ti dir impossible: Bentley inn leve. Li inn mase kot Colin ek amenn li so boul pou zwe. Paralize e ki pe ankadr eitanazi pou kapab retournen boul. Sa pa ti efè plesebo—bann lesyen pa reponn plesebo. Sa ti medsin kannabinoid ki finn fer sa ki farmaseutik pa ti kapab.

Bentley vive ankor di zan, mor natirelman an zan venn. Pandan sa bann zan-la, Colin inn develop bann formil cannabis spesializé pou sak kondisyon relasyon laj Bentley finn afrote. Nenrodegenerasyon inn menn li konpran propriyete niroprotektif CBG ek agonism PPARγ THCa pou proteksyon sel serye. Demans inn menn li rol CBC dan nirougenèz. Gloukoma inn menn li agonism CB1 THC pou diminye presyon intrakouler. Lartrit paralizan inn menn li devlop metod anti-enflamatoir multi-wout ki servis CBD, CBG, THCa, ek beta-caryophyllene travay atravé diferan sistèm reseptor simultaneman.

Kannabinoid selman pa ti ase. Bann kondisyon evolye Bentley ti bezwen sinerzi multi-kannabinoid. Sa se poukwa nou RSO konteni set kannabinoid—pa kom gimmik marketin, me akoz nesesite ti oblige. Presizyon farmaseutik ti enportan—lavi Bentley ti depan presizyon formil, pa devinèt.

Batay Pèsonel Colin: Depi Benzo Jiska Libète

Colin osi konnen depandans farmaseutik pèsonelman. Li ti pe lite avek PTSD ek adiksion benzodiazepine. Kan li ti deside brise lib depi Xanax, li ti fer ot-kou—enn exploit notwar difisil ek danzere—en servi konessans kannabinoid ki li ti devlop pou gard Bentley anvi.

Formil Peace Gummies ki inn vinn prodwi OilWell ti kreye pandan esperiment minwi pandan li ti pe lite kont withdrawal benzo. Pou asire soulaz rapid, nou osi ofri formil Peace Gummies an forma vape, ki Colin servi pèsonelman pou geriz so insomnia ek PTSD sever. Sa pa konessan teorik. Colin inn viv sa RSO malad viv: dezespere pou soulaz, farmaseutik ki pa mars, dekouver ki kannabinoid mars kan pil pa mars.

Sot Anba-Tè Jiska Legal: Vwayaz Entegrité

Avek letan, bann benefis terapeutik cannabis ki Colin finn dekouvri depi li pe esey sovinn la vi Bentley inn vinn kour nou travay. Li inn devlop bann formil ki doktè servis pou kondisyon konme maladi Crohn, IBS, kolèzèseratif, PTSD, adiksion benzo, ek insomnia. So fokis toultan ti pou fer cannabis aksesib ek efikas pou tou dimoun, inklan vegan, diyabétik, ek sa ki gayn bezwen lasante spesifik.

ABC13 KTRK Houston—premyas sours nouvèl Houston—inn prezante Colin ek OilWell Cannabis dan sèt segman nouvèl konplé de 2019 ziska 2023. Colin inn repitidman seleksyon kom primyer ekspè endistri pou kouvèrtir polisi ek prodwi kanabis dan katriyem pli gran sité Amerik. Okenn lot operatè kanabis Houston aparé avek sa frekans oubyen larzè-la.

Nou Filozofi: Onnete Olye Hype

Sitasion Colin depi premye fonn ABC13 Septanm 2019 kaptir nou filozofi perfekteman: “Mo pa pe esey vann bann dimoun lwil serpan. Mo pa pe esey vann bann dimoun lespwar, me ena ase rezèch deor ki bann dimoun zis bezwen konn e esey ek ena meyèr version posib pou baze zot opinyon lor ki donn li enn konnesans konn si li bon oubyen pa bon pou zot.”

Zordi, OilWell Cannabis opere depi Montrose, Houston, Texas. Depi 2019, nou inn jenere apepriman en milyon dolar revini an zan, gard rating Google près 5.0, e nou ena lisans Texas DSHS. Nou bann prodwi pa mas-prodiwi—zot kreye avek sans pèsonel, depi zèd lor anbalaz ziska bann formil andan. Tout zèd, formil, ek anbalaz kreye andan Houston, servi selman nou prop resèt ek lide.

Nou amenn pè sever Houston, rasin McAllen, e mantalite bann konstriktir dan tout nou fer, me nou pozisyon res simple: fer prodwi avek entansyon, reponn dirèkteman, e zanmem pretann kannabis bon pou tou dimoun.

Kat Pié OilWell RSO

Nou RSO pa RSO tradisionel Rick Simpson. I enn prodwi formile, multi-kannabinoid, enfòme par tradisyon RSO me ki sòt depi li an fason deliberé, motive pa prèv, ek konsev pou rezoud bann problem ki limit vizyon orizinel Rick Simpson.

1. Aksesiblite Olye Gatekeeping

Okenn kat medikal pa nesesè. Nenpwit dimoun laj venn-enn oubyen pli gran kapab achte. Nou livre otour peyi zanmen Etazini ek enternasyonèlman pou kliyan ki verifie legalite lokal—inklan Sesel. Simpson ti kwar medsin bizin aksesib pou tou dimoun; nou inn bati enn prodwi ek model distribisyon ki fer sa aksesib legal, menm pou bann zil dan Losenan Endyen.

Pou rezidan Sesel, sa voudir ou pa bezwen navigasyon program medikal konpleks ki pa egziste lokal. Ou kapab aksè nou bann prodwi dirèkteman, avek dokiman konple pou douane ek konpliyans legal.

2. Malad Kontrole Potans

THCa vann an forma asidik, pa psikoaktif. Ou deside si ou servi li brit pou benefis pa psikoaktif oubyen dekarboksilé li an delta-9 THC pou potans psikoaktif konple. Simpson ti kwar malad bizin kontrole zot prop medsin; nou inn enjenyer enn prodwi ki met sa kontrol-la dan ou lanmen atravé lachimie plito ke retorik.

Pou rezidan Sesel ki travay dan tourism, lasinn, oubyen servis gouvernman kot klarite mantal esansyel, sa voudir ou kapab servi forma brit pandan zournye e aktiv li lannwit kan ou bezwen fòs terapeutik.

3. Formil Kouvrisous

Nou piblie nou bann formil RSO konplemanman—chak kannabinoid, chak kantite miligram, chak pousantaz—pou ki nenpwit moun ki pa kapab pey prodwi kapab sous engradyan e fer zot prop version. Bann formil aparé pli lwen dan sa lid-la. Simpson ti donn so lwil gratis e ansegn bann dimoun ki fèr li; nou adpte sa ethos-la pou mache kannabinoid modern an vandant enn prodwi fabrike profesyonelman ek piblie resèt.

Pou rezidan Sesel ki konfrount defi ekonomik—petet apey apre sezon tourism lanmove oubyen pri lavi montan dan Victoria—sa metod kouvrisous voudir ou pa bloké. Si $129.99 se an delo ou kapasite, ou kapab sous bann kannabinoid deriva chanvre (kot legal) e kreye ou version servi nou spesifikasyon egzak.

Nou pa komanse sa metod kouvrisous avek RSO—li komanse avek Bentley. Lor nou paj “A propos”, nou finn pibliye resèt egzak pât dore CBD ki sov lavi Bentley:

Resèt Pât dore CBD pou Zanimo domestik:

• 1/2 tas poud kurkuma organik
• 1 tas dilo
• 1/3 tas lwil kokonat (pa rafine, organik)
• 1-2 kiyer pwav nwar fre (neseser pou absorpsyon)
• Lwil CBD (dòz depan gwosur zanimo domestik; konsilte veterinèr)

Melanj kurkuma ek dilo dan poilon sou fe low ize ziska form pât epés (7-10 minit). Ajoute lwil kokonat ek pwav. Les refredi, gard frèzèr pou jiska de semenn. Melanj avek manze zanimo domestik enn oubyen de fwa pa zournen.

Sa resèt-la gratis, itil, e demonstre nou karaktèr mye ke nenpwit kopi marketin.

4. Enfòme pa Prèv, Pa Gonflé Prèv

Bann sitasyon rezèch dan sa lid-la reprezant nou angazman pou edikasyon onèt lor sa ki syans dir vre. Simpson ti opere san aksè literati revi par pear; nou ena sa aksè-la e nou servi li pou distenge ant sa ki bon sipoute, sa ki pe emerz, ek sa ki gonflé.

Konpliyans Farm Bill ek Kad Legal pou Sesel

Farm Bill 2018 inn legalize chanvre ek prodwi deriva chanvre ki konten mwens ki 0.3% delta-9 THC pa pwa sek federal dan Etazini. Sa kad legal-la se fondasyon nou konsepsyon prodwi.

Nou RSO Lwil Sublingwal konten selman 90 miligram delta-9 THC dan tout bouche 30 mL—3 miligram par mL—byen anba siy 0.3%. Tout kannabinoid deriva chanvre. Prodwi legal dwa federal ek dan laplipar leta.

THCa se pre-kursor asidik, pa psikoaktif, pou delta-9 THC. Li pa li-mem delta-9 THC. Sa distinksyon-la legalman siyifikatif: THCa konfòm Farm Bond moman lavant akoz li pa konvèrti en delta-9 THC.

Siyifikasyon Pratik pou Sesel

Ou kapab legalman achte nou prodwi dan Sesel akoz li konten mwens ki 0.3% delta-9 THC moman lavant. Prodwi kapab fonksyon de fason:

Opsyon 1—Brit, Okenn Cho: Tou 1,500 miligram res kouma THCa—konpleman pa psikoaktif. Sa ideal pou servis pandan zournye dan Sesel, kit ou travay dan tourism, gouvernman, oubyen ou kouri bann biznis pitt dan Victoria. Ou gayn benefis anti-enflamatoir atravé inhibit COX-2 ek potansyel niroprotektif atravé agonism PPARγ [12] san okenn imparmans.

Opsyon 2—Totalman Aktive, Dekarboksilasyon Lakay: Chofe lwil 260°F (125°C) pandan 45-60 minit dan rési ver ki kapab al four konvèrti 1,500 miligram THCa an apepriman 1,315 miligram delta-9 THC. Anplis avek 90 mg ekzistan, sa donn apepriman 1,405 miligram delta-9 THC total—donn prodwi potans psikoaktif komparab RSO illegal tradisionel, antyèman disposisyon ou apré achat.

Lachimi Konversyon: THCa ena pwa molekil 358.47 g/mol. Proporsyon konversyon se apepriman 1 miligram THCa = 0.877 miligram delta-9 THC apré dekarboksilasyon.

Avètisman Legal Enportan: THCa konvèrti en delta-9 THC kan cho. Bann kliyan dan Sesel responsab pou konprann e konpliyans avek lwa lokal regar prodwi kannabinoid. Nou livre avek dokiman konple, Sertifik Analiz, ek risi. Bann kliyan enternasyonèl asept tout responsabilite douane ek legal. Toultan verifye reglementasyon Sesel aktyel regar prodwi deriva chanvre avan komannd.

Prodiksion San Solvant: Sekirite ou Kapab Konfyans

Prodiksion RSO tradisionel ti servi nafta oubyen alkol isopropil—okenn pa grad manze. Nafta se enn melanz idrokarbon petwolé konpleks ki kapab konteni benzene, toluene, ek lot konpozé toksik. Purz solvent inkonple kite rezidu potansyelman domazab.

Nou RSO pa prodwi ekstraksyon dan sans tradisionel. I enn melanz formilé distilat ek isolat kannabinoid individual konbine an proporsyon spesifik dan environman prodiksion kontrole. Okenn nafta. Okenn alkol isopropil. Okenn butane. Okenn solvent ekstraksyon pa egziste dan prodwi fini.

Nou servi lwil organik MCT (triglisérida mwayenne) kom baz porteur—enn lipid grad manze ki fasilite absorpsyon kannabinoid atravé tisu sublingwal e ki donn profil gou neutr, enn ameliorasyon siyifikatif konpare tekstir pike konsistans ek odèr rezidiel solvent RSO tradisionel.

Test lab terst parti kouvri potans kannabinoid, profil tèrpen, ek pane sekirite inklan pesitisd, metal lour, solvent rezidiel, ek kontaminan mikrob. Sertifik Analiz (COA) disponib sou demann e aksesib atravé nou sitwèb.

Portfolio Prodwi Konplet Nou

Anplas RSO, nou prodwi bann gamm prodwi kannabinoid, sak devlop depi konessans formil ki Colin inn bati pandan vwayaz di zan Bentley ek so prop eksperyans avek PTSD ek withdrawal benzo.

Asshole Peach — Nou prodwi pli popiler, partikilye favorizé pa veteran pou kapasite soulaz doulé e simptom PTSD san twa agresif. Sak bag peach gummy konteni 268 mg kannabinoid total: 28 mg Delta-9 THC, 50 mg Delta-8 THC, 20 mg Delta-10 THC, 20 mg THCo, 100 mg CBD, 50 mg CBG. Pri: $39.99.

Peace Gummies — Devlopé dirèkteman depi eksperyans pèsonel Colin avek PTSD ek adiksion benzodiazepine. Peace Gummies inn ed li kite Xanax ot-kou. Sak peach konteni 320 mg kannabinoid total: 30 mg CBN, 15 mg Delta-9 THC, 25 mg Delta-8 THC, 100 mg CBD, 150 mg CBG. Pri: $34.99.

SWEETEMintz — Bann bonbon mint peppermint san sir, 100% vegan pou diyabétik ek konsomater konsene lasante. Sak konteni 28 mg Delta-9 Nano THC, 100 mg Nano CBD, 50 mg CBG Isolat. Pri: $39.99.

Custom Creations — Nou ofri prodwi fèt sour mezir adapte bezwen spesifik. Kit sa implik proporsyon kannabinoid spesifik, forma livrasyon partikilye, oubyen formilasyon pou sirkonstans lasante inik, nou devlop prodwi siblé sou demann. Sa inklan formilasyon pou vegan, diyabétik, ek sa ki gayn bezwen lasante oubyen alimentèr spesifik.

De Forma Prodwi pou Rezidan Sesel

Nou ofri formil RSO an de wout livrasyon, sak konsev pou diferan ka-servis ek diferan profil farmakokinetik.

RSO Lwil Sublingwal — $129.99

• Volim: Bouche 30 mL (1 fl oz)
• Kannabinoid Total: 16,590 mg (553 mg par mL)
• Profil Kannabinoid: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Tèrpen Vivan: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Baz: Lwil organik MCT
• Dòz: Sirinnj gradué pou presizyon dòz an inkreman 0.1 mL
• Debut: 15-45 minit (absorpsyon sublingwal atravé mikoze oral)
• Pik Efè: 1-2 èr
• Dire: 4-6 èr
• Biodisponibilite: 13-19% (wout sublingwal kontoune partielman metabolisme foie premye pasaz)
• Dòz par Bouche: Apepriman 40-60 dòz depan grosir servis

RSO Katouch Vape — $49.99

• Volim: Katouch 1 gram
• Kannabinoid Total: 900 mg+
• Profil Kannabinoid: Menm proporsyon sik kannabinoid sis kon sublingwal (THCa otomatikman dekarboksilé a tèmperatur vape)
• Tèrpen Vivan: 5%+
• Konpatibilite: Batri universal 510-thread
• Debut: 1-2 minit (plis rapid wout livrasyon kannabinoid)
• Pik Efè: 10-15 minit
• Dire: 2-4 èr
• Biodisponibilite: 10-35% (varyab, depan teknik inhalasyon)
• Dekarboksilasyon Otomatik: THCa konvèrti delta-9 THC a tèmperatur vape (400-450°F)

Ki Fason Rezidan Sesel Bizin Swazir Forma

Ka Servis	Forma Rekomandé	Rezon
Soulaz rapid (doule akit, nye, panik)	Vape	Debut 1-2 minit kritik pou simptom kris
Soulaz soutnu (doule kronik, dormi)	Sublingwal	Dire 4-6 edr founi kouvèrtir tout-zournye oubyen tout-lannwit
Biodisponibilite maksimum	Sublingwal	13-19% absorpsyon pli hau ke laplipar wout oral
Portable ek diskresyon	Vape	Konpak, okenn mezir neseser, parfait pou vwayaz otour zil Sesel
Kontrole presizyon dòz	Sublingwal	Sirinnj gradué pèmèt inkreman 0.1 mL pou ajustman fin
Servis zournye pa psikoaktif	Sublingwal (brit)	THCa res inaktif, zéro imparmans pou travay oubyen kondwi dan Victoria
Servis lannwit psikoaktif	Sublingwal (dekarboksilé) oubyen Vape	THCa aktivé + delta-8 THC pou potans terapeutik

Gid Spesifik-Kondisyon pou Rezidan Sesel

Avètisman Enportan: Bann konteks swivan ki swiv yo enfòme pa rezèch kannabinoid sité atravé sa lid-la ek nou rasyon formil. Zot pa preskripsyon medikal, pa proto traitman apré FDA, ek pa sibstiti swen profesyonèl medikal. Sa bann prodwi-la pa finn evalué pa Food and Drug Administration ek pa entansyon pou dijnostike, traité, geri, oubyen prevni nenpwit maladi. Toultan konsilt ou doktè kalifie avan servi prodwi kannabinoid, sitou si ou gen enn kondisyon medikal, pran medikaman, oubyen ou ansent oubyen alait. Pa kondwi vehikil oubyen servi ekipman pandan ou anflas ek kannabinoid psikoaktif.

Konteks Spesifik Sesel: Sesel ena enn sistenm lasante pitt me ki ap grandi. Pandan ki Lopital Victoria ek lezot fasilite founi swen eksele, aksè pou klinik douleur spesializé, sipò onkoloji, oubyen servis lasante mantal kapab limité, sitou lor bann zil deor. Nou bann prodwi konsev pou komplimante, pa ranplas, ou swen medikal ekzistan. Si ou pe swiv traitman a Lopital Sesel oubyenn klinik prive dan Victoria, diskite servis kannabinoid avek ou doktè.

Nye ek Sipò Laptit Relasyon Kemoterapi

• Pre-kemo: 0.5-1.0 mL sublingwal apepriman 1 èr avan traitman
• Nye akit akit: 2-3 bouf vape pou soulaz imedyat (debut 1-2 minit)
• Post-kemo: 0.5 mL sublingwal chak 6 èr sel nesesite
• Sipò dormi pandant traitman: 1.0-2.0 mL sublingwal avan dormi (delivre 25-50 mg CBN)
• Prèv: prèv antiemetik delta-8 THC [9], prèv anti-nye delta-9 THC [1][13], tampon anksiolitik CBD [3]

Doule Kronik (Lartrit, Nirropati, Fibromyalji)

• Zournye: 0.3-0.5 mL sublingwal brit—founi benefis anti-enflamatoir san imparmans psikoaktif
• Lannwit: 0.5-1.0 mL sublingwal dekarboksilé—konbine soulaz doulé avek sipò dormi CBN
• Doule akit: Vape sel nesesite pou debut rapid
• Prèv: prèv doulé CBD [4], prèv doulé delta-9 THC [13], agonism CB2 beta-caryophyllene [24], inhibit COX-2 THCa [12]

Sipò Dormi

• Avan dormi: 1.0-2.0 mL sublingwal
• A 2.0 mL, sa delivre 50 mg CBN—nivo dòz ki etidye dan literati dormi 2024
• A 1.0 mL, sa delivre 25 mg CBN—anlè limit 20 mg asosyé avek diminisyon deranj dormi [16][17]
• Prèv: prèv dormi CBN [16][17], literati revi cannabis ek dormi

Lankieté ek Stress

• Soulaz zournye fonksyonel: 0.3 mL sublingwal brit—CBD ek CBG adres wout lankieté san imparmans
• Lannwit: 1.0 mL sublingwal—profil kannabinoid konplet inklan CBN pou arkitektir dormi
• Prèv: prèv lankieté CBD [3], farmakoloji CBG [7][8], efè entourage limonene [20]

Prinsip Titrasyon Jeneral pou Sesel

Koumanse ba, ale dousman. Kòmanse avek 0.25-0.5 mL sublingwal e evalye efè pandan 2-3 èr avan ogmanté. Repons individual varye baze sou pwa ko, metabolisme, tolerans, medikaman konko, ek lezot faktè. Klima tropical ek fason lavi Sesel kapab afekte metabolisme—rest idrate ek evit pran dòz dan cho ekstrè ziska ou konpran ou repons.

Livrazon dan Sesel: Ki Fason I Mars

Nou opere selon sistenm livrazon RSO jounen-mem dan Houston, me pou rezidan Sesel nou ofri livrazon enternasyonèl fidèl avek dokiman konple.

Livrazon Internasyonèl pou Sesel:

• Tou pakaz enklan dokiman konple, Sertifik Analiz (COA), ek risi pou douane
• Nou servi anbalaz diskret san brand cannabis vizib
• Trakazinn founi pou tout komannd
• Anbalaz resistan tèmperatir asire entegrite prodwi pandan vwayaz atravé Losenan Endyen
• Frê minima aplik; frê livrazon enternasional ekse e faktire kliyan
• Ou responsab pou verifye legalite aktyel Sesel regar prodwi deriva chanvre avek mwens ki 0.3% delta-9 THC
• Kontakte nou (832) 416-2816 oubyen [email protected] pou frè livrazon spesifik Sesel ek gid douane

Konsiderasyon Legal Sesel: Sesel gayn istorik lwa divg dwòg strik, me bann prodwi deriva chanvre avek kantite THC minimal kapab tom anba diferan reglman. Nou rekòmand kouma pratik konsilt avek otorite douane Sesel oubyen ekspè legal lokal avan komannd. Nou founi tout dokiman neseser pou demontre konpliyans Farm Bill, me responsabilite legal final repoz sou ou, kliyan.

Nou Bann Formil: Transparans Konple

Formil RSO Lwil Sublingwal

Kannabinoid	Kantite
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
Kannabinoid Total	16,590 mg

• Tèrpen Vivan: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Forma: Bouche 30 mL
• Kannabinoid aktif par mL: 553 mg
• Pri: $129.99

Formil Katouch RSO

Kannabinoid	Pousantaz
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Tèrpen Vivan: 5%+
• Forma: Katouch 1 Gram
• Pri: $49.99

Profil Tèrpen: De-de bann prodwi konteni menm set tèrpen—limonene (sitron-brillant), myrcene, caryophyllene (pwav/epis), pinene (fore frè), linalool (floral, lavender), humulene (later-bwa), ek terpinolene (pini-frwi).

Lasians Derier Sak Engradyan

CBD: Fondasyon

CBD ena prèv imen pli fò dan nou formil, partikilye pou disorder konvulsion [1][2]. Rev sistematik 2024 ek meta-analiz 316 participant atravé wit etid inn trouv efè anksiolitik siyifikan otik [3]. Pou douleur, rev 2024 konklid literati prometè me eterojène [4]. Pou dormi, rev 2023 trouv febles metodolojik reziste [5].

Preokipasyon sekirite: Meta-analiz 2023 inn idantifye sinyal vre pou elevazim lespasman foie ek posib blese foie indwit pa drug, sitou relevant pou prodwi oral konsantre e seting polifarmasi [6]. NCCIH osi alam kont dyare, somnolans, chanjman laptit, efè limood, ek entèraksyon drug-drug [1].

CBG: Niroprotektèr

CBG se pre-kursor biostinetik pou plizyè kannabinoid major avek propriyete farmakolojik distenge [7][8]. Rev diskite posib relevance pou disorder neurologik, maladi intesten enflamatoir, ek aktivite antibakteriyèl, me etid imen reziste esparz [7]. CBG komersyalman interesan AKOZ li pa explore—revenman souvan depase syans [7].

Delta-8 THC: Kousin Kontrovèsyal

Delta-8 THC gayn konpòtman farmakokinetik ek farmakodinamik largman similèr delta-9 THC me parèt mwins potan akòz afinite CB1 pli feb [9]. Rev 2023 finn trouv baz prèv dominé pa etid animal, lachimi prodwi, e preokipasyon lasante piblik plito ke esè imen for [10]. Preokipasyon kalite fabrikasyon siyifikatif [11]. Delta-8 bizin traité kom enn analòg THC psikoaktif avek aktivite farmakolojik ver me karakterizasyon sekirite inkonple [9]-[11].

THCa: Pouvwar Pre-kursor

THCa se pre-kursor asidik THC ek kapab reprezant enn gran part kontenu relasyon THC dan materyal plant brit [12]. THCa li-mem pa psikoaktif, me cho konvèrti li an THC [12]. Literati in vitro ek rodent sigere posibilite anti-enflamatoir, imunomodilatèr, niroprotektif, ek antineoplastik, me sa pa ekivalan ak rezilta imen etabli [12].

Delta-9 THC: Lame De-Bisz

NCCIH idantifye medikaman kontenant THC relevant pou nye relasyon kemoterapi, problem laptit HIV/AIDS, ek sertin rezilta douleur/skléroz multipl [1]. Rev sistematik 2022 finn trouv prodwi THC-hau kapab founi benefis douleur kout-term me ogmante etourdi, sedasyon, nye, ek diskontinyasyon traitman [13]. Farmakokinetik klasik montre THC inhalé: debut segonn a minit, pik 15-30 minit; THC oral: debut pli tar, pik pli tar, dire pli lonng [14].

Risk lasante mantal: Rev sistematik 2025 finn trouv asosyasyon defavorab konstan ant prodwi THC-konsantrasyon hau ek psychosis, schizophrenia, ek disorder servis cannabis, avek sinyal preokipan pou lankieté ek deprime [15]. Risk adisyonel inklan takykardi, chanjman presyon san, depandans, withdrawal, preokipasyon grosès, ek blese poumon relasyon vape [1][14][15].

CBN: Mit Dorimi

CBN marketé pou dormi, me prèv la feb. Rev narratif 2021 finn sennen 99 rezime etid imen, revi uit atik tèks-integral, ek finn trouv Okenn esey klinik ki servi kesyoner dormi valide oubyen polysomnografi formal ki kapab sipoute revenman dormi for [16]. Rev mise a zour 2024 konklid ki rezèch dormi cannabis global pa kontanpwar lakèl servis reyèl [17]. CBN se enn pli bon egzanp kot repitasyon kiltirèl depase prèv klinik [16][17].

CBC: Zouvè K-emerz

CBB gayn farmakodinamik ek farmakokinetik distenge konpare avek kannabinoid pli konnu [18]. Rev 2024 souligne zonn antinosif, antibakteriyen, ek anti-konvulsion kom sib rezèch interesan [18]. Me prodwi CBC par konsomater deza vand malgre ti prèv ki etabli efikasité klinik ou sekirite [18]. CBC antre kategori kannabinoid minor syansman kredib ki merite pli rezèch, pa aktif klinik deja valide [18][19].

Tèrpen: Plis ki Odè

Revenman tèrpen bezwen entèrpretasyon pli strik ke revenman kannabinoid. Anpil literati vini depi konpozé izolé, lwil esansyel, plant non-cannabis, oubyen model pre-klinik. Prèv robust efè entourage klinikman siyifikatif imen reziste limité [20][29].

Limonene: Rev 2021 dekri propriyete multifonksyonel inklan antioksidan, anti-enflamatoir, kardioprotektif, e gastroprotektif, me laplipar revenman vini literati non-imen [21]. Prodwi oksidasyon limonene se alèz kontak klinik [22].

Myrcene: Rev 2021 dekri propriyete anksiolitik, antioksidan, anti-enflamatoir, ek analjezik me di eksplisitman ki etid imen mank [23]. Revenman ki dir ki myrcene eksplik fasan “couch-lock” pli for ke prèv aktyel sipoute.

Caryophyllene: Aparé kom agonist selektif reseptor CB2, ki fer li partikilyèrman relevant farmakolojikman [24]. Aktion anti-enflamatoir, imunomodilatèr, antioksidan, niroprotektif, ek gastroprotektif diskite, me konfirmasyon klinik imen reziste limité [24].

Pinene: Rev lasante serye 2021 finn trouv sinyal antioksidan, anti-enflamatoir, ek niroprotektif ki jistifie etid fitir, me aksantir ke prèv majorite pre-klinik ek esey klinik byen-konsev mank [25]. Revenman lor ameliorasyon memwar oubyen kontra-efè kognitif THC reziste ipotèz, pa fek etabli [25].

Linalool: Diskite pou farmakoloji stress, limood, ek lasante serye [25][26]. Me, idrosiperoksit oksidizé linalool se alèz rekonesan [22]. Linalool syansman kredib me bezwen frèzir ki pridan olye revenman terapeutik fèm [25][26].

Humulene: Rev 2024 finn trouv prèv pre-klinik laj pou efè anti-enflamatoir, avek travay rodent ki sigere propriyete kannabimimétik atravé CB1 ek wout adenosine A2a [27]. Sa bann rezilta-la valab pou jenere ipotèz me pa etabli efikasité imen konstan.

Terpinolene: Pi piti karakterizé klinikman tèrpen nan profil nou. Rev sistematik 2021 ki sennen 2,449 dosye finn trouv prèv dominé pa etid in silico, in vitro, ek animal olye esey imen [28]. Menm rev efè entourage resan sipoute benefis tèrpen kon ipotèz esploratwar [20][29].

Limit Rezèch ek Entèrpretasyon

Sink reg kritik pou entèrprete rezèch cannabis:

1. Prèv tre inegal. CBD ek delta-9 THC sipoute deklarasyon pli detaye; lot bezwen pli pridan [1]-[29].
2. Ekstraksyon/molekil/sentetik/donn tèrpen pa entèchanjab. Enn erer komen se les prèv senn kategori reprezant lot.
3. Kannabinoid minor komersyalman interesan AKOZ zot pa explore. Revenman otour zot souvan anfle.
4. Kalite prodwi enportan otank ki idantite molekil. Presizyon etiket, kontaminasyon, sous-prodwi sinetik, varyab dòz, ek farmakokinetik depan wout tou materyel afekte rezilta [1][10][11][14].
5. Lachimi THCa chanje avek stokaz/cho. Stokaz ek cho kapab konvèrti kannabinoid asidik an kannabinoid nèt kon THC [12].

Bann Gonfleman Komen Pou Evite

Gonfleman: CBN se enn kannabinoid dormi pran klinikman.
Plis presi: Prèv dormi spesifik pou CBN reziste feb avek okenn baz for esey valide [16][17].

Gonfleman: Myrcene se enn sedativ imen pran ki eksplik couch-lock.
Plis presi: Myrcene ena biyoaktivite pre-klinik plazib, me prèv imen dirèk limité [20][23].

Gonfleman: Tèrpen gayn efè entourage pran klinikman.
Plis presi: Ipotèz entourage enfluwan me prèv klinik robust reziste limité [20][29].

Gonfleman: THCa toultan pa psikoaktif.
Plis presi: THCa li-mem pa THC, me cho konvèrti THCa an THC [12].

Gonfleman: Delta-8 THC an sekirite akoz li deriva chanvre.
Plis presi: Delta-8 THC psikoaktif, farmakolojikman pwoche delta-9 THC, e souvan mele avek preokipasyon kalite fabrikasyon [9]-[11].

Lekonklizyon Pratik pou Rezidan Sesel

• Aktif pli developpe pa prèv se CBD ek delta-9 THC.
• Delta-8 THC pa trivial; i psikoaktif avek karakterizasyon sekirite mwins robust ke delta-9 THC.
• THCa chanje avek prosesis ek pa bizin entèrprete mem fason forma brit vs cho.
• CBG, CBN, ek CBC syansman kredib me klinikman imatir konpare CBD ek THC.
• Tèrpen probablman kontribiy aròm, gou, e potentiyelman sertin biyoaktivite, me revenman terapeutik spesifik konpozé bizin fèt avek pridan.

Rekonèt Medya: Kredibilite Verifyé

Entre Septanm 2019 ek Avril 2023, ABC13 Houston inn prezante Colin Valencia ek OilWell Cannabis dan sèt segman nouvèl diferan. Sink diferan jounalis finn nou toultan sers sa bann zan-la: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, ek ekriven staff KTRK. Okenn lot operatè kanabis Houston aparé avek sa frekans oubyen larzè-la.

15 Septanm 2019: “Texas CBD businesses booming” – Premye fonn nou kot Colin ti dir: “Mo pa pe esey vann bann dimoun lwil serpan. Mo pa pe esey vann bann dimoun lespwar, me ena ase rezèch deor ki bann dimoun zis bezwen konn e esey ek ena meyèr version posib pou baze zot opinyon lor ki donn li enn konnesans konn si li bon oubyen pa bon pou zot.”

22 Mas 2021: “Entrepreneur creates direct-to-consumer business” – Colin ti eksplik: “Doulé vini an plizyèr form.”

24 Me 2021: “What is Delta 8 THC” – Echanj ikonik Steve Campion: “Maybe you want to get high.” Sa fonn envestigativ vin enn pli segman cannabis ABC13 referanse.

20 Out 2021: “Houston CBD shop giving away free products for COVID vaccine” – Nou inn donn apepriman $35,000 prodwi (1,000 caviar pre-rolls) pou ankouraz vaksinasyon, an kowodinasyon avek sité Houston.

19 Oktòb 2021: “Texas ban over once legal hemp product Delta 8” – Nou inn retire tout prodwi Delta-8 avan anfosman ek averti lot operatè ki pe voye entèrmed narkotik Echedule I san konprann.

7 Oktòb 2022: “Biden marijuana pardon” – Colin ti devwale so istorik kondanmasyon pèsonel marijuana: “Mo kontan pou get dimoun pa blese ankor pour sa.”

21 Avril 2023: “Marijuana industry getting creative” – Framing “Renaissance” Colin: “Lekel pe vini enn moman enportan ki bizin pran plezier ankor.”

Sa bann fonn-la pa materyal marketin. Zot segman nouvèl endepandan, kontrole editorialman depi afilye ABC major-market ki repitidman idantifye Colin kom lavwa plis kredib dan endistri kanapis legal Houston. Sa se rekonèt ki pa kapab achte—selman ganyen.

Komannd depi Sesel: Pròch Et Ou

Nou konpran ki komannd prodwi cannabis pou Sesel egzij konfyans ek klarite. Vo egzakt ki fason proced:

1. Verifye Legalite: Kontakte douane Sesel oubyen ekspè legal lokal pou konfirm reglman aktyel regar prodwi deriva chanvre avek <0.3% delta-9 THC. Nou founi tout dokiman, me ou dwe konfirm aksèptasyon lokal.

2. Swazir Ou Forma: Deside ant lwil sublingwal (dire pli lonng, dòz presi) oubyen katouch vape (soulaz rapid, portable). Anpil rezidan Sesel swazir de-de—sublingwal pou mantni zournye, vape pou moman kris.

3. Pass Ou Komannd: Vizite oilwellcbd.com ek swazir ou bann prodwi. Dan kas, ou pou resevwa opsyon livrazon enternasyonèl ek frè. Pou Sesel, nou rekòmand livrazon avek trakazinn.

4. Dokimantasyon: Nou enklan Sertifik Analiz (COA) ki montre konteni kannabinoid egzak, konfirm <0.3% delta-9 THC. Sa demontre konpliyans Farm Bill pou ofisyèl douane Sesel.

5. Responsabilite Douane: Ou asept tout risk douane ek legal. Pandan ke nou finn sikse voye plizyèr peyi, Sesel ena so prop kad reglementer. Nou pa kapab garanti degagement douane, me nou founi tout dokiman pou maksimize ou posibilite.

6. Sipò: Imel [email protected] avek “Seychelles Order” dan satin pou asistans primordyal. Nou pou guid ou atravé prosesis e reponn nenpwit kestyon lor livrazon dan Losenan Endyen.

Laponse Final pou Sesel

OilWell Cannabis, nou pa la pou vann ou lespwar fòs oubyen gerizon mirak. Nou la akoz nou inn viv dezespere ki get bann ki nou anmou soufert e ki trouv solisyon vre kan medsin konvansionel pa ti mars. Istoar Bentley pa marketin—se nou loriginn. Batay Colin avek PTSD ek benzo pa pitch lavant—se so eksperyans vive.

Nou piblie nou bann formil akoz Simpson ti ansegn nou ki medsil bizin aksesib. Nou sité 29 sours revi par pear akoz ou merite syans onèt, hype pa. Nou ofri potans kontrole par malad akoz ou bizin deside sa ki antre dan ou ko.

Rezidan Sesel rankont defi lasante unique—zeyografi zile limite aksè pou swen spesializé, douleur kronik kapab pa traité, ek resous lasante mantal kapab tiré. Nou bann prodwi pa ranplas ou doktè a Lopital Sesel oubyen ou spesialis dan Victoria. Zot enn zouti ou kapab servi ansanm avek swen profesyonèl, avek transparans konple sou sa ki prèv montre vreman.

Kit ou enn malad kanser ki pe rod sipò, enn veteran avek PTSD, kikenn ki pe redwi benzodiazepine, oubyen zis kurie lor syans kannabinoid, ou merite tout fonprè edikasyon—pa yon version tronke ki antre dan enn limit mo. Sa lid-la se nou angazman pou ou.

Kontakte nou: (832) 416-2816 | [email protected]
Vizite: oilwellcbd.com
Adrès: 810 Richmond Avenue, Houston, TX 77006, USA

Nou baze dan Houston, me nou misyon al atravé oseyan—pou Sesel, pou ou, pou nenpwit dimoun pe rod repons onèt dan enn lemonn konfizyon cannabis. Bentley inn leve ek mache. Colin inn vènken benzo. Petet sa zouti-la se sa ki ed ou pran ou pwochen etap forward.

Sa lid-la baze lor rezèch revi par pear [1]-[29] ek sous istorik dokumenté -. Tou spesifikasyon prodwi, formil, ek enfòmasyon konpanny piblie konman Mars 2026. Pou rezidan Sesel, tanpri verifye lwa lokal aktyel avan komannd.

ENGLISH

Rick Simpson Oil (RSO) in Seychelles: The Complete Guide by OilWell Cannabis

Living in Seychelles means understanding that when conventional medicine falls short, nature often holds answers we’ve barely begun to explore. If you’re here reading this, chances are you or someone you love is facing a health challenge that prescription medications haven’t solved—perhaps chronic pain that makes walking on Mahé’s beautiful beaches painful, sleep issues that leave you exhausted during busy workdays in Victoria, or the weight of anxiety that no beach meditation seems to lift. Maybe you’ve heard whispers about Rick Simpson Oil, that mysterious cannabis extract that people across the world are turning to when they feel they’ve run out of options.

We get it. We’ve been there too. At OilWell Cannabis, we didn’t start as a corporation chasing profits—we started as desperate people searching for real solutions. Our founder Colin Valencia watched his beloved dog Bentley go from paralyzed and facing euthanasia to walking again, all because of a cannabinoid formula he created. That moment changed everything. It taught us that cannabis isn’t about getting high—it’s about getting your life back.

This guide is our complete, evidence-based introduction to Rick Simpson Oil for Seychelles residents. We’re publishing every detail—our exact formulas, the science behind each ingredient, how we evolved beyond traditional RSO, and most importantly, how this product can legally and safely reach you here in Seychelles. No hype. No secrets. Just the most comprehensive RSO education available anywhere.

Who is Rick Simpson?

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or medical researcher—he was a power engineer and maintenance worker, a blue-collar tradesman whose path into cannabis advocacy began not with academic curiosity, but with personal suffering.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. According to Simpson, the medications he was prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused .

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, where THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials .

The Moment That Started It All

The pivotal moment in Simpson’s story came in 2003. He reported that three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil and the foundation of everything that followed .

Important context: Simpson’s account is presented here as his personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement.

The Crusade That Reached Seychelles

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil. Operating from his property in Maccan, Nova Scotia, he began making oil in large quantities and giving it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others .

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. This film became one of the most widely shared cannabis advocacy films of its era, introducing millions worldwide—including people in Seychelles—to the concept of concentrated cannabis oil as medicine .

When Advocacy Meets Law

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support, he was raided again in 2009. Facing continued legal pressure, Simpson eventually left Canada for Europe, continuing his advocacy from abroad .

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, detailing his experience and oil-making process, and maintained phoenixtears.ca as his primary platform .

The Claims vs. The Evidence

Rick Simpson made expansive therapeutic claims. He stated that RSO could cure cancer—including terminal cases—and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions. He maintained that cannabis oil could cure cancer and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge .

What Simpson was not: He was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally .

What the preclinical literature shows: In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis in certain cancer cell lines . Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids .

What the preclinical literature does not show: These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast. No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer .

Institutional positions:

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment .
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer [1].
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS—not cancer cure [1].

What Simpson got right: He drew attention to cannabinoids as a serious area of biomedical research when the world was ignoring it. His advocacy helped create the political, cultural, and social conditions for the legal cannabis industry and cannabinoid research infrastructure that exists today. The term RSO remains the most recognized name for full-spectrum cannabis extract .

What he overstated: The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment in place of proven oncologic therapies carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern .

The Traditional RSO Protocol

Simpson’s core treatment recommendation was a structured oral protocol delivering 60 grams of concentrated cannabis oil over approximately 90 days. Here’s the detailed breakdown as Simpson described it :

Goal: Consume 60 grams of concentrated, high-THC cannabis oil over roughly 90 days. Simpson considered this the minimum necessary for serious cancer treatment.

Week 1: Begin with a dose approximately the size of half a grain of dry rice—roughly 10 to 15 milligrams of oil—taken three times per day (morning, afternoon, and before bed). Total daily intake: approximately 30 to 45 milligrams.

Weeks 2 through 5: Double the dose approximately every four days. By the end of this escalation period—roughly four to five weeks in—the target is to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses of 333 milligrams each.

Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day and continue until the full 60 grams have been consumed.

Administration methods: Simpson recommended oral ingestion (sublingual or swallowed) as primary, topical application for skin cancers, and acknowledged inhalation for immediate symptom relief but not as primary treatment.

Tolerance and psychoactive effects: Simpson maintained that patients would develop significant tolerance to THC’s psychoactive effects within three to four weeks. He recommended initial doses at night and warned against driving or operating machinery during titration.

Important context for evaluating this protocol:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or well-documented case series evaluating this specific protocol for any condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency.
• Very high THC exposure. At peak dosing, patients consume roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day—a dose far exceeding anything studied in controlled clinical settings. The FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [1][13][14][15].
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment introduces harm beyond the oil itself.

Traditional RSO vs. Modern Formulated RSO

The term RSO is now used loosely across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. Here’s how traditional RSO compares to our modern formulation:

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets (553 mg/mL)
Lab testing	Not available or performed	Full panel testing (potency, pesticides, heavy metals, residual solvents, microbial)
Residual solvents	Significant risk with naphtha	Controlled and tested to FDA Class 3 limits
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted with 29 peer-reviewed citations

Why Our Formulas Diverge from Traditional RSO

Our formulations depart from Simpson’s original method in deliberate, evidence-motivated ways:

Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew. Our formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests potential benefit from cannabinoid diversity [20][29].

Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. We include live terpenes at 5% with a specific seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Terpene bioactivity is plausible and supported at the preclinical level [20][21][23][24][25][26][27][28][29].

THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. Our sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity [12].

Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC—often 60 to 90 percent of total cannabinoid content. Our sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg).

Product format innovation. Simpson envisioned only one format: an oral oil administered from a syringe. We offer both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own formulation acknowledging that different delivery routes have different pharmacokinetic profiles [14].

The Origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts—vibrant culture and a thriving retail sector, yet deeply affected by poverty and limited opportunities. Reynosa, on the other hand, is an industrial hub plagued by violence and cartel activity.

Colin’s childhood in McAllen exposed him to both opportunities and challenges. By sixteen, he had to leave home for good after experiencing every form of violence imaginable. Despite the dangers, Colin did not fall into the darkest paths. He focused on cannabis, seeing it as a safer alternative, and grew up in the traditional cannabis world long before legalization, learning the plant intimately.

Later, Colin became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—defines OilWell’s approach.

Bentley’s Story: The Real Reason We Exist

Our company’s origin story begins with a dog named Bentley. Bentley was more than just a pet—he was family. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing more suffering.

But giving up on Bentley was not an option. In a desperate search for alternatives, a rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?” That question changed everything.

Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It wasn’t a cure, but it was hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect—dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. This is why our RSO contains seven cannabinoids—not as a marketing gimmick, but because necessity demanded it. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

Colin’s Personal Battle: From Benzos to Freedom

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat notoriously difficult and dangerous—using the cannabinoid knowledge he developed keeping Bentley alive.

The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, we also offer the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

From Underground to Legitimate: A Journey of Integrity

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 KTRK Houston—Houston’s number-one news source—featured Colin and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city. No other Houston cannabis operator appears with that frequency or across that breadth.

Our Philosophy: Honesty Over Hype

Colin’s quote from his first ABC13 feature in September 2019 captures our philosophy perfectly: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Today, OilWell Cannabis operates from Montrose, Houston, Texas. Since 2019, we’ve generated approximately one million dollars in annual revenue, maintained a near-5.0 Google rating, and hold a Texas DSHS license. Our products aren’t mass-produced—they’re carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only our own recipes and ideas.

We bring Houston grit, McAllen roots, and a builder’s mindset to everything we do, but our posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

The Four Pillars of OilWell RSO

Our RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

1. Accessibility Over Gatekeeping

No medical card is required. Anyone age twenty-one or older can purchase. We ship nationwide across the United States and internationally to customers who verify local legality—including Seychelles. Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally, even to islands in the Indian Ocean.

For Seychelles residents, this means you don’t need to navigate complex medical cannabis programs that may not exist locally. You can access our products directly, with full documentation for customs and legal compliance.

2. Patient-Controlled Potency

THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; we engineered a product that puts that control in your hands through chemistry rather than rhetoric.

For Seychelles residents who work in tourism, fishing, or government services where mental clarity is essential, this means you can use the raw form during the day and activate it at night when you need therapeutic strength.

3. Open-Source Formulas

We publish our complete RSO formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford the product can source ingredients and make their own version. The formulas appear later in this guide. Simpson gave his oil away for free and taught people how to make it; we adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe.

For Seychelles residents facing economic challenges—perhaps struggling after a slow tourist season or rising living costs in Victoria—this open-source approach means you’re not locked out. If $129.99 is beyond your reach, you can source hemp-derived cannabinoids (where legal) and create your own version using our exact specifications.

We didn’t start this open-source approach with RSO—it started with Bentley. On our About Us page, we published the actual CBD golden paste recipe that saved Bentley’s life:

CBD Golden Paste Recipe for Pets:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (crucial for absorption)
• CBD oil (dosage depends on pet size; consult a veterinarian)

Mix turmeric and water in a saucepan over low heat until thick paste forms (7-10 minutes). Add coconut oil and pepper. Cool, store in refrigerator for up to two weeks. Mix with pet food once or twice daily.

This recipe is free, useful, and demonstrates our character better than any marketing copy.

4. Evidence-Informed, Not Evidence-Overstating

The research citations in this guide represent our commitment to honest education about what science actually says. Simpson operated without access to peer-reviewed literature; we have that access and use it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill Compliance and Legal Framework for Seychelles

The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level in the United States. This legal framework is the foundation of our product design.

Our RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3% threshold. All cannabinoids are hemp-derived. The product is legal under federal law and in most states.

THCa is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The Practical Significance for Seychelles

You can legally purchase our product in Seychelles because it contains less than 0.3% delta-9 THC at the time of sale. The product can function in two ways:

Option 1—Raw, No Heat: All 1,500 milligrams stays as THCa—completely non-psychoactive. This is ideal for daytime use in Seychelles, whether you’re working in tourism, government, or running a small business in Victoria. You get anti-inflammatory benefits via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12] with zero impairment.

Option 2—Fully Activated, Home Decarboxylation: Heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams, this yields approximately 1,405 milligrams of total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

Conversion Chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation.

Important Legal Notice: THCa converts to delta-9 THC when heated. Customers in Seychelles are responsible for understanding and complying with local laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility. Always verify Seychelles’ current regulations regarding hemp-derived products before ordering.

Solvent-Free Production: Safety You Can Trust

Traditional RSO production used naphtha or isopropyl alcohol—neither food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, and other toxic compounds. Incomplete solvent purging leaves potentially harmful residues.

Our RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

We use organic MCT oil (medium-chain triglycerides) as the carrier base—a food-grade lipid that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile, a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through our website.

Our Complete Product Portfolio

Beyond RSO, we produce a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach — Our most popular product, particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive. Each peach gummy ring contains 268mg total cannabinoids: 28mg Delta-9 THC, 50mg Delta-8 THC, 20mg Delta-10 THC, 20mg THCo, 100mg CBD, 50mg CBG. These sell for $39.99.

Peace Gummies — Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. Each peach contains 320mg total cannabinoids: 30mg CBN, 15mg Delta-9 THC, 25mg Delta-8 THC, 100mg CBD, 150mg CBG. These sell for $34.99.

SWEETEMintz — Zero-sugar, 100% vegan peppermint hard candy for diabetic and health-conscious consumers. Each contains 28mg Delta-9 Nano THC, 100mg Nano CBD, 50mg CBG Isolate. These sell for $39.99.

Custom Creations — We offer custom-made products tailored to specific needs. Whether it involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, we design targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

Two Product Formats for Seychelles Residents

We offer our RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil — $129.99

• Volume: 30 mL bottle (1 fl oz)
• Total Cannabinoids: 16,590 mg (553 mg per mL)
• Cannabinoid Profile: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Base: Organic MCT oil
• Dosing: Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak Effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19% (sublingual route partially bypasses first-pass liver metabolism)
• Doses per Bottle: Approximately 40 to 60 doses depending on serving size

RSO Vape Cartridge — $49.99

• Volume: 1-gram cartridge
• Total Cannabinoids: 900 mg+
• Cannabinoid Profile: Same six-cannabinoid ratio as sublingual (THCa auto-decarboxylates at vaping temperature)
• Live Terpenes: 5%+
• Compatibility: 510-thread universal battery
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak Effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35% (variable, dependent on inhalation technique)
• Automatic Decarboxylation: THCa converts to delta-9 THC at vaping temperature (400 to 450°F)

How Seychelles Residents Should Choose Between Formats

Use Case	Recommended Format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset is critical for breakthrough symptoms
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration provides all-day or all-night coverage
Maximum bioavailability	Sublingual	13-19% absorption is higher than most oral routes
Portability and discretion	Vape	Compact, no measuring required, perfect for travel around Seychelles islands
Precise dosing control	Sublingual	Graduated dropper allows 0.1 mL increments for fine-tuning
Daytime non-psychoactive use	Sublingual (raw)	THCa stays inactive, zero impairment for work or driving in Victoria
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC for therapeutic potency

Condition-Specific Guidance for Seychelles Residents

Important Disclaimer: The following contexts are informed by cannabinoid research cited throughout this guide and by our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Seychelles-Specific Context: Seychelles has a small but growing healthcare system. While Victoria Hospital and other facilities provide excellent care, access to specialized pain clinics, oncology support, or mental health services may be limited, especially on outer islands. Our products are designed to complement, not replace, your existing medical care. If you’re undergoing treatment at Seychelles Hospital or a private clinic in Victoria, discuss cannabinoid use with your physician.

Chemotherapy-Related Nausea and Appetite Support

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)
• Evidence: delta-8 THC antiemetic evidence [9], delta-9 THC nausea evidence [1][13], CBD anxiolytic buffering [3]

Chronic Pain (Arthritis, Neuropathy, Fibromyalgia)

• Daytime: 0.3 to 0.5 mL raw sublingual—provides anti-inflammatory benefits without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep Support

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN—the dosage level investigated in 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance [16][17]
• Evidence: CBN sleep evidence [16][17], cannabis and sleep review literature

Anxiety and Stress

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety pathways without impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture
• Evidence: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage effect [20]

General Titration Principle for Seychelles

Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors. Seychelles’ tropical climate and lifestyle may affect metabolism—stay hydrated and avoid taking doses in extreme heat until you understand your response.

Delivery to Seychelles: How It Works

We operate the only same-day RSO delivery system in Houston, but for Seychelles residents, we offer reliable international shipping with full documentation.

International Shipping to Seychelles:

• All packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes
• We use discreet packaging with no cannabis branding visible
• Tracking is provided for all orders
• Temperature-stable packaging ensures product integrity during the journey across the Indian Ocean
• Minimum flat-fee shipping applies; excessive international shipping costs are billed to the customer
• You are responsible for verifying Seychelles’ current legality of hemp-derived products with less than 0.3% delta-9 THC
• Contact us at (832) 416-2816 or [email protected] for Seychelles-specific shipping quotes and customs guidance

Seychelles Legal Considerations: Seychelles has historically strict drug laws, but hemp-derived products with minimal THC content may fall under different regulations. We strongly recommend consulting with Seychelles customs authorities or a local legal expert before ordering. We provide all necessary documentation to demonstrate Farm Bill compliance, but ultimate legal responsibility rests with you, the customer.

Our Formulas: Complete Transparency

RSO Sublingual Oil Formula

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30mL bottle
• Active cannabinoids per mL: 553mg
• Price: $129.99

RSO Vape Cartridge Formula

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 Gram cartridge
• Price: $49.99

Terpene Profile: Both products contain the same seven terpenes—limonene (citrus-bright), myrcene, caryophyllene (pepper/spice), pinene (forest-fresh), linalool (floral, lavender), humulene (earthy, woody), and terpinolene (piney, fruity).

The Evidence Behind Every Ingredient

CBD: The Foundation

CBD has the strongest human evidence in our formula, particularly for seizure disorders [1][2]. A 2024 systematic review and meta-analysis of 316 participants across eight studies found statistically significant anxiolytic effects [3]. For pain, a 2024 review concluded the literature is promising but heterogeneous [4]. For sleep, a 2023 review found methodological weaknesses remain [5].

Safety concerns: A 2023 meta-analysis identified real signals for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH also flags diarrhea, sleepiness, appetite changes, mood effects, and drug-drug interactions [1].

CBG: The Neuroprotector

CBG is the biosynthetic precursor to several major cannabinoids with pharmacologically distinct properties [7][8]. Reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but human studies remain sparse [7]. CBG is commercially interesting BECAUSE it’s underexplored—claims frequently outrun the science [7].

Delta-8 THC: The Controversial Cousin

Delta-8 THC has broadly similar pharmacokinetic and pharmacodynamic behavior to delta-9 THC but appears less potent due to weaker CB1 affinity [9]. A 2023 scoping review found the evidence base dominated by animal studies, product chemistry, and public-health concerns rather than strong human trials [10]. Manufacturing quality concerns are significant [11]. Delta-8 should be treated as a psychoactive THC analogue with real pharmacologic activity but incomplete safety characterization [9]-[11].

THCa: The Precursor Power

THCa is the acidic precursor of THC and may represent a large share of THC-related content in raw plant material [12]. THCa itself is not psychoactive, but heating converts it to THC [12]. In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes [12].

Delta-9 THC: The Double-Edged Sword

NCCIH identifies THC-containing medicines as relevant for chemotherapy-related nausea, HIV/AIDS appetite issues, and some pain/multiple sclerosis outcomes [1]. A 2022 systematic review found high-THC products may provide short-term pain benefit but increase dizziness, sedation, nausea, and treatment discontinuation [13]. Classic pharmacokinetics show inhaled THC: onset seconds to minutes, peak 15-30 minutes; oral THC: later onset, later peak, longer duration [14].

Mental health risks: A 2025 systematic review found consistent unfavorable associations between high-concentration THC products and psychosis, schizophrenia, and cannabis use disorder, with concerning signals for anxiety and depression [15]. Additional risks include tachycardia, blood pressure changes, dependency, withdrawal, pregnancy concerns, and vape-related lung injury [1][14][15].

CBN: The Sleep Myth

CBN is marketed for sleep, but the evidence is weak. A 2021 narrative review screened 99 human-study abstracts, reviewed eight full-text articles, and found NO clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims [16]. A 2024 updated review concluded that overall cannabinoid sleep research still doesn’t match real-world use scale [17]. CBN is one of the clearest examples where cultural reputation exceeds clinical evidence [16][17].

CBC: The Emerging Player

CBC has distinct pharmacodynamics and pharmacokinetics compared to better-known cannabinoids [18]. A 2024 review highlighted antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets [18]. However, over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety [18]. CBC belongs in the category of scientifically credible minor cannabinoids that deserve more research, not already-validated clinical actives [18][19].

Terpenes: More Than Aroma

Terpene claims need even stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models. Robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene: A 2021 review describes multifunctional properties including antioxidant, anti-inflammatory, cardioprotective, and gastroprotective effects, but most claims come from nonhuman literature [21]. Limonene oxidation products are clinically relevant contact allergens [22].

Myrcene: A 2021 review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties but explicitly states human studies are lacking [23]. Claims that myrcene reliably explains “couch-lock” are stronger than current evidence supports.

Caryophyllene: Stands out as a selective CB2 receptor agonist, making it especially relevant pharmacologically [24]. Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, and gastroprotective actions are discussed, but human clinical confirmation remains limited [24].

Pinene: A 2021 brain-health review found antioxidant, anti-inflammatory, and neuroprotective signals justifying future study, but emphasized that evidence is mostly preclinical and well-designed clinical trials are lacking [25]. Claims about memory improvement or counterbalancing THC cognitive effects remain hypotheses, not settled facts.

Linalool: Discussed for stress, mood, and brain-health pharmacology [25][26]. However, oxidized linalool hydroperoxides are recognized allergens [22]. Linalool is scientifically credible but requires cautious phrasing rather than firm therapeutic promises.

Humulene: A 2024 scoping review found broad preclinical evidence for anti-inflammatory effects, with some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27]. These findings are valuable for hypothesis generation but don’t establish consistent human efficacy.

Terpinolene: The least clinically characterized terpene in our profile. A 2021 systematic review of 2,449 records found evidence dominated by in silico, in vitro, and animal studies rather than human trials [28]. Even recent entourage reviews frame terpene benefits as exploratory [20].

Research Limits and Interpretation

Five critical rules for interpreting cannabis research:

1. Evidence is highly uneven. CBD and delta-9 THC support the most detailed statements; others require more caution [1]-[29].
2. Extract/molecule/synthetic/terpene data aren’t interchangeable. One common error is letting evidence from one category stand in for another.
3. Minor cannabinoids are commercially interesting BECAUSE they’re underexplored. Claims around them often become inflated.
4. Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect real-world results [1][10][11][14].
5. THCa chemistry changes with storage/heating. Storage and heating can convert acidic cannabinoids into neutral cannabinoids like THC [12].

Common Overstatements to Avoid

Overstatement: CBN is a clinically proven sleep cannabinoid.
More accurate: Specific sleep evidence for CBN remains weak with no strong validated-trial base [16][17].

Overstatement: Myrcene is a proven human sedative that explains couch-lock.
More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof is limited [20][23].

Overstatement: Terpenes have proven entourage effects in patients.
More accurate: Entourage hypotheses are influential but robust clinical proof remains limited [20][29].

Overstatement: THCa is always nonpsychoactive.
More accurate: THCa itself is not THC, but heating converts THCa into THC [12].

Overstatement: Delta-8 THC is safe because it’s hemp-derived.
More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing quality concerns [9]-[11].

Practical Takeaways for Seychelles Residents

• The most evidence-developed actives are CBD and delta-9 THC.
• Delta-8 THC is not trivial; it’s psychoactive with less robust safety characterization than delta-9 THC.
• THCa changes with processing and shouldn’t be interpreted the same way in raw vs. heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature compared to CBD and THC.
• The terpenes likely contribute to aroma, flavor, and potentially some bioactivity, but compound-specific human therapeutic claims should be made carefully.

Media Recognition: Verified Credibility

Between September 2019 and April 2023, ABC13 Houston featured Colin Valencia and OilWell Cannabis in seven distinct news segments. Five different reporters sought us out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or breadth.

September 15, 2019: “Texas CBD businesses booming” – Our origin feature where Colin stated: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

March 22, 2021: “Entrepreneur creates direct-to-consumer business” – Colin explained: “Pain comes in a lot of different forms.”

May 24, 2021: “What is Delta 8 THC” – Steve Campion’s iconic exchange: “Maybe you want to get high.” This investigative feature became one of the most widely referenced ABC13 cannabis segments.

August 20, 2021: “Houston CBD shop giving away free products for COVID vaccine” – We gave away approximately $35,000 in product (1,000 caviar pre-rolls) to encourage vaccination, coordinating with the city of Houston.

October 19, 2021: “Texas ban over once legal hemp product Delta 8” – We proactively removed all Delta-8 products before enforcement and warned other operators who were unknowingly shipping Schedule I narcotics.

October 7, 2022: “Biden marijuana pardon” – Colin revealed his personal marijuana conviction history: “I would love to see people not get hurt for this anymore.”

April 21, 2023: “Marijuana industry getting creative” – Colin’s “Renaissance” framing: “Right now is actually a pretty important time that should be enjoyed now.”

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin as the most credible voice in Houston’s legal cannabis industry. That is recognition that cannot be purchased—it can only be earned.

Ordering from Seychelles: Your Next Steps

We understand that ordering cannabis products to Seychelles requires trust and clarity. Here’s exactly how to proceed:

1. Verify Legality: Contact Seychelles customs or a local legal expert to confirm current regulations on hemp-derived products with <0.3% delta-9 THC. We provide all documentation, but you must confirm local acceptance.

2. Choose Your Format: Decide between sublingual oil (longer-lasting, precise dosing) or vape cartridge (fast relief, portability). Many Seychelles residents choose both—sublingual for daily maintenance, vape for breakthrough moments.

3. Place Your Order: Visit oilwellcbd.com and select your products. At checkout, you’ll receive international shipping options and costs. For Seychelles, we recommend tracked shipping.

4. Documentation: We include a Certificate of Analysis (COA) showing exact cannabinoid content, confirming <0.3% delta-9 THC. This demonstrates Farm Bill compliance for customs officials in Seychelles.

5. Customs Responsibility: You accept all customs and legal risk. While we’ve successfully shipped to multiple countries, Seychelles has its own regulatory framework. We cannot guarantee customs clearance, but we provide every document to maximize your chances.

6. Support: Email [email protected] with “Seychelles Order” in the subject line for priority assistance. We’ll walk you through the process and answer any questions about shipping to the Indian Ocean.

Final Thoughts for Seychelles

At OilWell Cannabis, we’re not here to sell you false hope or miracle cures. We’re here because we’ve lived the desperation of watching loved ones suffer and finding real solutions when conventional medicine fell short. Bentley’s story isn’t marketing—it’s our origin. Colin’s battle with PTSD and benzos isn’t a sales pitch—it’s his lived experience.

We publish our formulas because Simpson taught us that medicine should be accessible. We cite 29 peer-reviewed sources because you deserve honest science, not hype. We offer patient-controlled potency because you should decide what goes into your body.

Seychelles residents face unique healthcare challenges—island geography limits access to specialized care, chronic pain may be undertreated, and mental health resources may be stretched thin. Our products aren’t a replacement for your doctor at Seychelles Hospital or your specialist in Victoria. They’re a tool you can use alongside professional care, with full transparency about what the evidence actually shows.

Whether you’re a cancer patient seeking supportive care, a veteran with PTSD, someone tapering off benzodiazepines, or simply curious about cannabinoid science, you deserve the full depth of education—not a truncated version that fits an arbitrary word count. This guide is our commitment to you.

Contact us: (832) 416-2816 | [email protected]
Visit: oilwellcbd.com
Address: 810 Richmond Avenue, Houston, TX 77006, USA

We’re Houston-based, but our mission reaches across oceans—to Seychelles, to you, to anyone searching for honest answers in a world of cannabis confusion. Bentley got up and walked. Colin conquered benzos. Maybe this is the tool that helps you take your next step forward.

This guide is based on peer-reviewed research [1]-[29] and documented historical sources -. All product specifications, formulas, and company information are published as of March 2026. For Seychelles residents, please verify current local laws before ordering.

---